NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

Phase 2 Recruiting 304 enrolled Kaiser Permanente Beth Israel Deaconess Medical Center · collab Cedars-Sinai Medical Center · collab National Heart, Lung, and Blood Institute (NHLBI) · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery

Timeline

Start: 2021-09-13
Primary completion: 2025-04-30
Completion: 2025-06-30

Publications

Scurt FG, Bose K, Mertens PR, Chatzikyrkou C, Herzog C. Cardiac Surgery-Associated Acute Kidney Injury. Kidney360. 2024 Jun 1;5(6):909-926. doi: 10.34067/KID.0000000000000466. Epub 2024 May 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nicotinamide	Other / unclassified	3 g	Oral

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

Summary

Timeline

Publications

Drugs

Indications